FDA Approves St. Jude Medical, Inc. (NYSE:STJ) Paddle Lead For Chronic Pain Management


Dallas, Texas 07/21/2015 (Financialstrend) – St. Jude Medical, Inc. (NYSE:STJ) has received the FDA approval for the industry’s first MR-Conditional 5-Column Paddle Lead, for use in managing chronic pain.  Available for use with the company’s lead Protégé MRI System, the paddle lead will allow patients to undergo safe head and extremity MRI scans. The approval follows the recent approval of the MR-conditional labeling for Octrode percutaneous leads.

 Lateral Simulation Enhanced

 The approval is a big achievement for St. Jude Medical, Inc. (NYSE:STJ), which has over the past year introduced a series of MR-conditional implantable pulse generators with a view to improving chronic pain therapies.  Penta Paddle lead is designed to give physicians the broadest area for lateral simulation coverage, expected to enhance selective stimulation of nerve fibers.

 Specific targeting should make it is easy for physicians to tailor therapy to patient’s unique pain pattern. St. Jude Medical, Inc. (NYSE:STJ) group president Eric S Fain believes the recent approvals adds to the company’s chronic pain portfolio, which should enhance  further growth of the neuromodulator business. The company plans to improve the access of its industry leading chronic pain therapies especially for patients who need head and extremity MRI scans.

 Approval of Invisible Trial System

Chronic pain affects more than a billion people worldwide providing a huge market base for St. Jude Medical, Inc. (NYSE:STJ) therapies. The condition is widespread than heart disease cancer and diabetes combined.

St Jude Medical has also seen its Invisible Trial System receive the FDA approval having received the CE Mark in June. The wireless system leverages Apple Inc. (NASDAQ:AAPL) technology to provide patients an improved and discreet spinal cord stimulation trial experience, seen as an effective way of managing chronic pain.   The new system makes it easy for patients to evaluate their SCS therapy.

 TheStreet research firm currently rates St Jude as a ‘Buy’ citing strengths in its solid stock performance as well as growth in earnings per share in the recent quarter.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.